<Suppliers Price>

Cambendazol

Names

[ CAS No. ]:
26097-80-3

[ Name ]:
Cambendazol

[Synonym ]:
Cambenzole
Carbamic acid, N-[2-(4-thiazolyl)-1H-benzimidazol-6-yl]-, 1-methylethyl ester
Novazole
Isopropyl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate
Equiben
Camvet
(2-thiazol-4-yl-1(3)H-benzoimidazol-5-yl)-carbamic acid isopropyl ester
CBDZ
propan-2-yl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate
cambendazole
Carbamic acid, (2-(4-thiazolyl)-1H-benzimidazol-5-yl)-, 1-methylethyl ester
Isopropyl 2-(4-thiazolyl)-5-benzimidazolecarbamate
NOE [French]
Noviben
Bonlam
[2-(4-thiazolyl)-1H-benzimidazol-5-yl]carbamic acid 1-methylethyl ester
5-isopropoxycarbonylamino-2-(4'-thiazolyl)-benzimidazole
Camdan
Cambendazol

Biological Activity

[Description]:

Cambendazole is one of the most effective agents for the therapy of human strongyloidiasis and [1].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Others >> Others

[References]

[1]. Bicalho SA, et al. Cambendazole in the treatment of human strongyloidiasis. Am J Trop Med Hyg. 1983 Sep;32(5):1181-3.

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Melting Point ]:
212-214℃ (ethyl acetate hexane )

[ Molecular Formula ]:
C14H14N4O2S

[ Molecular Weight ]:
302.352

[ Exact Mass ]:
302.083740

[ PSA ]:
108.14000

[ LogP ]:
2.90

[ Index of Refraction ]:
1.694

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DD6538000
CHEMICAL NAME :
5-Benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester
CAS REGISTRY NUMBER :
26097-80-3
LAST UPDATED :
199612
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C14-H14-N4-O2-S
MOLECULAR WEIGHT :
302.38
WISWESSER LINE NOTATION :
T56 BM DNJ GMVOY1&1 C- ET5N CSJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
80480 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
60400 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
60800 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
80800 ug/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
348 mg/kg
SEX/DURATION :
female 6-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
348 mg/kg
SEX/DURATION :
female 6-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
75 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
75 mg/kg
SEX/DURATION :
female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

MUTATION DATA

TYPE OF TEST :
Mutation test systems - not otherwise specified
TEST SYSTEM :
Mammal - domestic Leukocyte
DOSE/DURATION :
1 mg/L
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 31,505,1976

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H361

[ Precautionary Statements ]:
P281

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
63

[ Safety Phrases ]:
36/37

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
DD6538000

Synthetic Route

Precursor & DownStream

Articles

The Hymenolepis diminuta-golden hamster (Mesocricetus auratus) model for the evaluation of gastrointestinal anticestode activity.

J. Parasitol. 90(4) , 898-9, (2004)

A novel laboratory anticestode assay was developed using Hymenolepis diminuta in the hamster. The commercial anticestode compounds, praziquantel, bunamidine, and niclosamide were active against patent...

Structural requirements for the induction of cytochromes P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes.

Biochem. Biophys. Res. Commun. 220(3) , 789-94, (1996)

The effect of sulfur-containing benzimidazoles (thiabendazole, 5-hydroxy-thiabendazole, cambendazole) and sulfur-free derivatives (benzimidazole, carbendazim and 5-hydroxycarbendazim) on cytochrome P4...

Controlled tests of activity of several antiparasitic compounds against natural infections of Haemonchus contortus and other helminths in lambs from a flock established in 1962.

Am. J. Vet. Res. 54(3) , 406-10, (1993)

Antiparasitic activity of several compounds was evaluated over a long period (about 25 years) in the same flock of sheep. Haemonchus contortus was of special interest, including its relation to drug r...


More Articles